One ongoing study proposes that empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor commonly used to treat diabetes, may prove effective in treating PAH in humans. This evidence concerns the gene SLC5A2 and diabetes mellitus.